Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | IDH2 | P48735 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | TERT | O14746 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15671751 | 0.82 | ALDH1A1 (0.54) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL14869745 | 0.82 | LMNA (0.55) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL2453813 | 0.82 | GAA (0.73) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL14869409 | 0.81 | ALDH1A1 (0.77) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL2452995 | 0.79 | ALDH1A1 (0.64) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL15671750 | 0.79 | NFKB1 (0.54) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL15671741 | 0.79 | MAPT (0.60) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL5471897 | 0.79 | NPC1 (0.50) | ALDH1A1CA1CA2CA9CA12 | |
| SCHEMBL2455305 | 0.77 | ALDH1A1 (0.49) | ALDH1A1CA1CA2CA9GAA | |
| SCHEMBL10598128 | 0.76 | GAA (0.64) | ALDH1A1CA1CA2CA9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197858-B1 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2014-07-02 | — | — | EP | claimed |
| US-8722674-B2 | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-05-13 | — | — | US | claimed |
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | HANALL PHARMACEUTICAL COMPANY, LTD (KR) | 2011-09-29 | — | — | US | claimed |
| EP-2197858-B1 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL BIOPHARMA CO LTD (KR) | 2014-07-02 | — | — | EP | disclosed |
| US-8722674-B2 | 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-05-13 | — | — | US | disclosed |
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | HANALL PHARMACEUTICAL COMPANY, LTD (KR) | 2011-09-29 | — | — | US | disclosed |
| EP-2197858-A2 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Hanall Pharmaceutical Company LTD. (KR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009028891-A2 | 1,3,5-TRIAZINE-2,4,6-TRIAMINE COMPOUND OR PHARMACEUTICAL ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HANALL PHARMACEUTICAL COMPANY. LTD (KR) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237587-A1 | 1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same | TP53, TP53BP1, SLC5A1 | ALDH1A1 1243/4885CA1 3191/4885CA2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.